GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genmab AS (STU:GE9) » Definitions » Pretax Margin %

Genmab AS (STU:GE9) Pretax Margin % : 55.92% (As of Dec. 2024)


View and export this data going back to . Start your Free Trial

What is Genmab AS Pretax Margin %?

Pre-Tax margin is calculated as Pre-Tax Income divided by its Revenue. Genmab AS's Pre-Tax Income for the three months ended in Dec. 2024 was €483 Mil. Genmab AS's Revenue for the three months ended in Dec. 2024 was €864 Mil. Therefore, Genmab AS's pretax margin for the quarter that ended in Dec. 2024 was 55.92%.

The historical rank and industry rank for Genmab AS's Pretax Margin % or its related term are showing as below:

STU:GE9' s Pretax Margin % Range Over the Past 10 Years
Min: 34.22   Med: 50.58   Max: 66.86
Current: 42.57


STU:GE9's Pretax Margin % is ranked better than
95.21% of 1003 companies
in the Biotechnology industry
Industry Median: -134.73 vs STU:GE9: 42.57

Genmab AS Pretax Margin % Historical Data

The historical data trend for Genmab AS's Pretax Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genmab AS Pretax Margin % Chart

Genmab AS Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Pretax Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 58.39 46.55 47.88 34.22 42.57

Genmab AS Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Pretax Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 21.16 41.42 39.37 31.03 55.92

Competitive Comparison of Genmab AS's Pretax Margin %

For the Biotechnology subindustry, Genmab AS's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Genmab AS's Pretax Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Genmab AS's Pretax Margin % distribution charts can be found below:

* The bar in red indicates where Genmab AS's Pretax Margin % falls into.


;
;

Genmab AS Pretax Margin % Calculation

Pretax margin - also known as pretax profit margin is the ratio of Pretax Income divided by net sales or Revenue, usually presented in percent.

Genmab AS's Pretax Margin for the fiscal year that ended in Dec. 2024 is calculated as

Pretax Margin=Pre-Tax Income (A: Dec. 2024 )/Revenue (A: Dec. 2024 )
=1228.798/2886.414
=42.57 %

Genmab AS's Pretax Margin for the quarter that ended in Dec. 2024 is calculated as

Pretax Margin=Pre-Tax Income (Q: Dec. 2024 )/Revenue (Q: Dec. 2024 )
=482.991/863.672
=55.92 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Genmab AS  (STU:GE9) Pretax Margin % Explanation

The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.

The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.

It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.

The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.


Genmab AS Pretax Margin % Related Terms

Thank you for viewing the detailed overview of Genmab AS's Pretax Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Genmab AS Business Description

Address
Carl Jacobsens Vej 30, Valby, DNK, 2500
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.

Genmab AS Headlines

No Headlines